Searched for
IMATINIB MESYLATE
Zydus Cadila gets USFDA nod to market generic cancer drugThe company has received final approval from the US Food and Drug Administration (USFDA) to market its product which is a generic version o...- Wockhardt gets USFDA nod for generic cancer drugWockhardt's Imatinib Mesylate tablets are a generic version of Gleevec, marketed in USA and other countries by Novartis.
- Indian companies get USFDA nod for 14 1st-time generic drugs in 2015Indian pharma firms accounted for 14 of total 90 first-time generic drug approvals granted by the United States Food and Drug Administratio...
- Sun Pharma launches Imatinib Mesylate, incentives to US leukemia patientsDrug maker Sun Pharmaceuticals launched Imatinib Mesylate, the generic copy of anti-cancer drug Gleevec, in the US market enjoying 180 days...
- Sun Pharma gets boost with US FDA approval for GleevecSun Pharmaceutical announced it received approval from the US FDA for generic copies of Gleevec, a drug that treats chronic myeloid leukemi...
- Sun Pharma takes Novartis to US Court, seeks permission to market Glivec in USUntil and unless Sun obtains a court decision of non-infringement and/or invalidity on the ’051 patent, it faces the risk of patent infring...
- Novartis lost patent case on technical groundNovartis lost its case on technical grounds. It failed to establish that the drug’s new form was sufficiently patentable.
- Will not invest on R&D in India: NovartisNovartis said it will not invest on R&D in India and move it to favourable destinations following the SC order rejecting its patent plea on...
- Supreme Court's decision on Novartis to benefit poor patients: Pharma companiesNovartis, however, said: "This ruling is a setback for patients that will hinder medical progress for diseases without effective treatment ...
- Novartis appeal excludes technical memberThe Union Government today informed the Madras High Court that the Intellectual Property Appellate Board (IPAB) could exclude technical mem...
- HC to hear Novartis case on October 8The Madras High Court will hear on October 8, Novartis' objection to the appointment of S Chandrasekaran, former Controller General of the ...
- Pharma MNCs bullying govt with China sword?The Madras High Court ruled that section 3(d) of the Indian Patents Act was constitutional.
- HC suspends hearings in Novartis' Glivec caseHearings in Novartis’ appeal against the rejection of patent for its anti-cancer drug Glivec have been suspended yet again, after the Madra...
- Glivec patent appeal's pendingNovartis has lost its challenge against the Indian government on the question of patent for incremental innovation, but its specific appeal...
- HC rejects petition by NovartisHC dismisses a petition filed by Novartis, challenging the constitutional validity of the Sect 3 (d) of the patents (amendment) act 2005.
- Madras HC to rule on Novartis’ patent caseWhen Novartis AG was accused of jeopardising patients’ access to generic medicines in India last year, the Swiss drug giant thought it woul...
- Novartis challenges Patents Act provisionFollowing the rejection of its patent application for anti-cancer drug Glivec, Swiss pharmaceutical giant Novartis is not only challenging ...
- Novartis takes on patent law in Glivec caseFollowing rejection of its patent application for anti-cancer drug Glivec, Swiss pharmaceutical giant Novartis AG is not only challenging t...
- Wockhardt's product refused patentThe patent office in Mumbai has rejected Wockhardt’s application for a product patent for its product - nadifloxacin - a topical antibiotic...
- Wait 'n watch: Exclusive marketing rights won't be granted soonThere will be no more exclusive marketing right grants in a hurry. The Controller General of Patents and Trademarks has decided to wait for...
Load More
